ガイストリッヒ ニュース

19. November 2020

Geistlich Derma-Gide® reaches an important milestone

Complex wounds do not heal easily: This is where our highly refined Advanced Wound Matrix Geistlich Derma-Gide® can provide clinical benefits to those suffering from chronic wounds. The General Services Administration (GSA) in the United States has now included Geistlich Derma-Gide® in the Federal Supply Schedule (FSS) for Veterans Administration medical facilities. With this listing, the product reaches an important milestone, as it is now available to all US veteran hospitals and practices.

This GSA approval paves the way for physicians and staff of veterans' administration health facilities to use Geistlich Derma-Gide® for the treatment of wounds that are difficult to heal. The product is approved by the U.S. Food and Drug Administration (FDA) for a variety of indications, including diabetic foot ulcers, venous leg ulcers, surgical wounds and first and second-degree burns.

Unique properties

The two-layer product design of Geistlich Derma-Gide® mimics the structural organization of human skin, thus facilitating the ingrowth of cells. For this matrix, which is currently available on the US market, Geistlich uses two different, specific porcine source tissues. The Geistlich scientists transformed the source tissue into a high-tech designed matrix. This provides the precise properties required to support wound healing. Geistlich Derma-Gide® received further recognition by being named one of the ten "top innovations" in the American scientific journal "PodiatryToday" in 2020 (Volume 33 | Number 7 | July 2020). Geistlich thus repeatedly stands for pioneering progress and as a driver of regeneration.